We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYK's MedSurg and Neurotechnology posted 16.7% growth, offset by margin pressure from inflation and FX.
Stryker Corporation (SYK - Free Report) posted robust second-quarter 2025 results, with broad-based momentum across its core businesses. Net sales grew 11.1% year over year to $6.1 billion, while organic sales improved 10.2%. Adjusted earnings per share (EPS) of $3.13 exceeded the consensus mark, reflecting healthy volume growth, favorable pricing and disciplined execution.
Management raised full-year organic sales growth guidance to 9.5-10% and adjusted EPS to $13.40-$13.60. Despite strong execution and innovation-led growth, competitive risks, macro pressures and elevated valuation suggest limited near-term upside.
Shares of Stryker have gained 3.8% so far this year compared with the industry’s growth of 5.7%. The broader Medical sector has declined 1.8% and S&P 500 Index hassurged 14.9% in the said period.
Image Source: Zacks Investment Research
Short-Term Growth Drivers
Orthopaedics Strength and Mako Adoption: Orthopaedics posted a strong rebound, fueled by rising elective procedure volumes and the continued uptake of the Mako robotic platform. Demand was especially robust in knee and hip implants, with global Mako placements gaining meaningful traction. Knee implants rose 6.3%, while hip implants advanced 8.9%, both supported by higher procedure volumes and accelerating robotic adoption.
Management noted that Mako procedures surpassed the 2-million milestone in the second quarter, with international markets contributing significantly as hospitals expand their robotic-assisted surgery capabilities. Rising Mako placements are boosting implant volumes and embedding robotics more deeply into orthopedic care. These dynamics reinforce Stryker’s technology leadership and highlight the near-term momentum of robotics in enhancing surgical efficiency and patient outcomes.
MedSurg and Neurotechnology Contributions: The MedSurg and Neurotechnology segment delivered 16.7% organic growth, supported by strong demand for patient handling systems, surgical instruments, and neurovascular solutions. Hospitals are actively refreshing capital equipment and investing in advanced surgical technologies, driving greater utilization across Stryker’s broad portfolio. Neurotechnology’s strong growth isfueled by robust demand in craniomaxillofacial and stroke care products. Collectively, these segments provide stability and balance to Stryker’s overall growth trajectory.
Long-Term Growth Drivers
Global Expansion and Emerging Markets: Stryker’s international business remains a long-term growth lever, with double-digit gains in Asia-Pacific and Latin America. In emerging markets, low penetration of robotic-assisted surgery and orthopedic procedures provides a significant runway. The company is investing in localized manufacturing and R&D to enhance competitiveness and capture market share, but executing effectively in price-sensitive markets will be crucial to sustaining momentum.
Innovation and Pipeline Development: Stryker’s innovation pipeline remains strong, with developments across orthopaedics, trauma, extremities, and endoscopy. The Mako platform is steadily broadening its procedural reach, while upcoming launches in sports medicine and next-generation endoscopy are set to reinforce the company’s competitive positioning. With R&D investment consistently above 6% of sales, management continues to prioritize innovation. However, maintaining a leadership position will depend on how rapidly new technologies are adopted compared to competing solutions.
Synergies and Portfolio Expansion: Stryker’s portfolio expansion strategy is showing clear results, supported by targeted acquisitions in spine and neurovascular markets. The 2022 purchase of Wright Medical’s spine assets strengthened Stryker’s position in minimally invasive spine procedures, broadening its Orthopaedics platform. Likewise, the 2023 acquisition of Cerus Endovascular added innovative stent and coil technologies, reinforcing leadership in stroke care within the Neurotechnology franchise.
Management highlighted that these acquisitions are already generating integration benefits, including expanded R&D collaboration and more efficient distribution networks. Stryker is also unlocking cross-selling opportunities, using Mako placements as a gateway to bundled solutions across orthopaedics, spine, and neurovascular. This ecosystem strategy strengthens hospital relationships, generates recurring revenues from implants and instruments, and underpins sustainable, long-term growth.
SYK’s Sales & EPS Estimates
Image Source: Zacks Investment Research
Challenges
Competitive Pressures in Robotics and Devices: Competition in robotic orthopaedics is intensifying, with Zimmer Biomet (ZBH - Free Report) , Johnson & Johnson (JNJ - Free Report) and Medtronic (MDT - Free Report) advancing rival platforms. Sustaining differentiation will require continued evidence of superior outcomes and cost-effectiveness. Broader medtech competition also poses pricing and margin pressures, particularly in capital-intensive markets.
Macro and Cost Pressure: Persistent inflation, currency volatility, and rising wages continue to weigh on performance. Regulatory hurdles in international markets add further uncertainty for new product launches. Despite delivering strong top-line growth, management noted that inflationary costs, FX headwinds, and wage pressures had a clear impact on margins in the second quarter of 2025. Foreign exchange dampened revenue growth, while higher raw material and logistics costs pressured gross margin, partially offset by productivity gains. Wage inflation, particularly in U.S. manufacturing, also lifted operating expenses, muting some of the benefits from favorable pricing.
Regulatory and Supply-Chain Risks: Supply-chain reliability has improved compared to the disruptions during 2022-2023, but management noted ongoing bottlenecks in electronic components and specialty materials that limited product availability in certain geographies. Geopolitical instability remains a risk factor, with tariffs and trade restrictions contributing to higher input costs. Regulatory hurdles for product approvals in international markets also continue to slow time-to-market for new launches.
Competitors’ Update
Zimmer Biomet posted another solid quarter in the second quarter of 2025 with net sales of approximately $2.08 billion, up 7% year over year (2.8% organic), driven by robust demand in its hip, knee, and surgical portfolios. The company raised its full-year EPS guidance to $8.10-$8.30, underscoring confidence in continued orthopedic momentum. ZBH also highlighted a significant 16% sales increase in its Sports Medicine, Extremities & Trauma (“S.E.T.”) segment, which contributed meaningfully to both revenue growth and margin stability amid tightening operating conditions.
Johnson & Johnson delivered a strong second-quarter 2025 performance, with sales worth $23.7 billion, marking a 5.8% year-over-year increase, and adjusted EPS of $2.77. The company raised its full-year sales forecast to $93.2-$93.4 billion and EPS guidance to $10.80-$10.90 due to lower-than-expected tariff costs.
Within the medtech division, JNJ reported 6% growth, bolstered by robust performance across device segments, especially in electrophysiology. JNJ’s diversified portfolio and favorable macro dynamics have helped it outperform, although headwinds like legal litigation and competitive pressure remain.
Medtronic delivered a solid second-quarter 2025 performance, with revenues of roughly $8.58 billion (reflecting an 8.3% year-over-year increase) and EPS of 81 cents, while adjusted EPS was $1.26. Despite at least a 9-cent negative impact from foreign exchange, MDT raised its full-year organic revenue growth and EPS guidance, reflecting resilience in core franchises such as TAVR, diabetes, spine and neuromodulation. Medtronic continues to benefit from strong innovation-led demand and operational discipline, even amid FX headwinds and persistent cost pressures.
Stryker’s second-quarter performance highlights its strong execution across orthopaedics, MedSurg and Neurotechnology while sustaining margin discipline. Its robust pipeline, global expansion and integration synergies create a compelling long-term outlook. However, premium valuation, competitive intensity and macro risks temper the near-term investment case. While Stryker remains a high-quality medtech leader with durable advantages, the stock’s risk-reward profile suggests patience. Stryker currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
Key Takeaways
Stryker Corporation (SYK - Free Report) posted robust second-quarter 2025 results, with broad-based momentum across its core businesses. Net sales grew 11.1% year over year to $6.1 billion, while organic sales improved 10.2%. Adjusted earnings per share (EPS) of $3.13 exceeded the consensus mark, reflecting healthy volume growth, favorable pricing and disciplined execution.
Management raised full-year organic sales growth guidance to 9.5-10% and adjusted EPS to $13.40-$13.60. Despite strong execution and innovation-led growth, competitive risks, macro pressures and elevated valuation suggest limited near-term upside.
Shares of Stryker have gained 3.8% so far this year compared with the industry’s growth of 5.7%. The broader Medical sector has declined 1.8% and S&P 500 Index hassurged 14.9% in the said period.
Image Source: Zacks Investment Research
Short-Term Growth Drivers
Orthopaedics Strength and Mako Adoption: Orthopaedics posted a strong rebound, fueled by rising elective procedure volumes and the continued uptake of the Mako robotic platform. Demand was especially robust in knee and hip implants, with global Mako placements gaining meaningful traction. Knee implants rose 6.3%, while hip implants advanced 8.9%, both supported by higher procedure volumes and accelerating robotic adoption.
Management noted that Mako procedures surpassed the 2-million milestone in the second quarter, with international markets contributing significantly as hospitals expand their robotic-assisted surgery capabilities. Rising Mako placements are boosting implant volumes and embedding robotics more deeply into orthopedic care. These dynamics reinforce Stryker’s technology leadership and highlight the near-term momentum of robotics in enhancing surgical efficiency and patient outcomes.
MedSurg and Neurotechnology Contributions: The MedSurg and Neurotechnology segment delivered 16.7% organic growth, supported by strong demand for patient handling systems, surgical instruments, and neurovascular solutions. Hospitals are actively refreshing capital equipment and investing in advanced surgical technologies, driving greater utilization across Stryker’s broad portfolio. Neurotechnology’s strong growth isfueled by robust demand in craniomaxillofacial and stroke care products. Collectively, these segments provide stability and balance to Stryker’s overall growth trajectory.
Long-Term Growth Drivers
Global Expansion and Emerging Markets: Stryker’s international business remains a long-term growth lever, with double-digit gains in Asia-Pacific and Latin America. In emerging markets, low penetration of robotic-assisted surgery and orthopedic procedures provides a significant runway. The company is investing in localized manufacturing and R&D to enhance competitiveness and capture market share, but executing effectively in price-sensitive markets will be crucial to sustaining momentum.
Innovation and Pipeline Development: Stryker’s innovation pipeline remains strong, with developments across orthopaedics, trauma, extremities, and endoscopy. The Mako platform is steadily broadening its procedural reach, while upcoming launches in sports medicine and next-generation endoscopy are set to reinforce the company’s competitive positioning. With R&D investment consistently above 6% of sales, management continues to prioritize innovation. However, maintaining a leadership position will depend on how rapidly new technologies are adopted compared to competing solutions.
Synergies and Portfolio Expansion: Stryker’s portfolio expansion strategy is showing clear results, supported by targeted acquisitions in spine and neurovascular markets. The 2022 purchase of Wright Medical’s spine assets strengthened Stryker’s position in minimally invasive spine procedures, broadening its Orthopaedics platform. Likewise, the 2023 acquisition of Cerus Endovascular added innovative stent and coil technologies, reinforcing leadership in stroke care within the Neurotechnology franchise.
Management highlighted that these acquisitions are already generating integration benefits, including expanded R&D collaboration and more efficient distribution networks. Stryker is also unlocking cross-selling opportunities, using Mako placements as a gateway to bundled solutions across orthopaedics, spine, and neurovascular. This ecosystem strategy strengthens hospital relationships, generates recurring revenues from implants and instruments, and underpins sustainable, long-term growth.
SYK’s Sales & EPS Estimates
Image Source: Zacks Investment Research
Challenges
Competitive Pressures in Robotics and Devices: Competition in robotic orthopaedics is intensifying, with Zimmer Biomet (ZBH - Free Report) , Johnson & Johnson (JNJ - Free Report) and Medtronic (MDT - Free Report) advancing rival platforms. Sustaining differentiation will require continued evidence of superior outcomes and cost-effectiveness. Broader medtech competition also poses pricing and margin pressures, particularly in capital-intensive markets.
Macro and Cost Pressure: Persistent inflation, currency volatility, and rising wages continue to weigh on performance. Regulatory hurdles in international markets add further uncertainty for new product launches. Despite delivering strong top-line growth, management noted that inflationary costs, FX headwinds, and wage pressures had a clear impact on margins in the second quarter of 2025. Foreign exchange dampened revenue growth, while higher raw material and logistics costs pressured gross margin, partially offset by productivity gains. Wage inflation, particularly in U.S. manufacturing, also lifted operating expenses, muting some of the benefits from favorable pricing.
Regulatory and Supply-Chain Risks: Supply-chain reliability has improved compared to the disruptions during 2022-2023, but management noted ongoing bottlenecks in electronic components and specialty materials that limited product availability in certain geographies. Geopolitical instability remains a risk factor, with tariffs and trade restrictions contributing to higher input costs. Regulatory hurdles for product approvals in international markets also continue to slow time-to-market for new launches.
Competitors’ Update
Zimmer Biomet posted another solid quarter in the second quarter of 2025 with net sales of approximately $2.08 billion, up 7% year over year (2.8% organic), driven by robust demand in its hip, knee, and surgical portfolios. The company raised its full-year EPS guidance to $8.10-$8.30, underscoring confidence in continued orthopedic momentum. ZBH also highlighted a significant 16% sales increase in its Sports Medicine, Extremities & Trauma (“S.E.T.”) segment, which contributed meaningfully to both revenue growth and margin stability amid tightening operating conditions.
Johnson & Johnson delivered a strong second-quarter 2025 performance, with sales worth $23.7 billion, marking a 5.8% year-over-year increase, and adjusted EPS of $2.77. The company raised its full-year sales forecast to $93.2-$93.4 billion and EPS guidance to $10.80-$10.90 due to lower-than-expected tariff costs.
Within the medtech division, JNJ reported 6% growth, bolstered by robust performance across device segments, especially in electrophysiology. JNJ’s diversified portfolio and favorable macro dynamics have helped it outperform, although headwinds like legal litigation and competitive pressure remain.
Medtronic delivered a solid second-quarter 2025 performance, with revenues of roughly $8.58 billion (reflecting an 8.3% year-over-year increase) and EPS of 81 cents, while adjusted EPS was $1.26. Despite at least a 9-cent negative impact from foreign exchange, MDT raised its full-year organic revenue growth and EPS guidance, reflecting resilience in core franchises such as TAVR, diabetes, spine and neuromodulation. Medtronic continues to benefit from strong innovation-led demand and operational discipline, even amid FX headwinds and persistent cost pressures.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
Conclusion
Stryker’s second-quarter performance highlights its strong execution across orthopaedics, MedSurg and Neurotechnology while sustaining margin discipline. Its robust pipeline, global expansion and integration synergies create a compelling long-term outlook. However, premium valuation, competitive intensity and macro risks temper the near-term investment case. While Stryker remains a high-quality medtech leader with durable advantages, the stock’s risk-reward profile suggests patience. Stryker currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.